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Abstract
We have explored the threshold of tolerance of three unrelated cell types to treatments with potential cytoprotective peptides bound to Tat48–57
and Antp43–58 cell-permeable peptide carriers. Both Tat48–57 and Antp43–58 are well known for their good efficacy at crossing membranes of
different cell types, their overall low toxicity, and their absence of leakage once internalised. Here, we show that concentrations of up to 100 μM of
Tat48–57 were essentially harmless in all cells tested, whereas Antp43–58 was significantly more toxic. Moreover, all peptides bound to Tat48–57 and
Antp43–58 triggered significant and length-dependent cytotoxicity when used at concentrations above 10 μM in all but one cell types (208F rat
fibroblasts), irrespective of the sequence of the cargo. Absence of cytotoxicity in 208F fibroblasts correlated with poor intracellular peptide uptake,
as monitored by confocal laser scanning fluorescence microscopy. Our data further suggest that the onset of cytotoxicity correlates with the
activation of two intracellular stress signalling pathways, namely those involving JNK, and to a lesser extent p38 mitogen-activated protein
kinases. These responses are of particular concern for cells that are especially sensitive to the activation of stress kinases. Collectively, these results
indicate that in order to avoid unwanted and unspecific cytotoxicity, effector molecules bound to Tat48–57 should be designed with the shortest
possible sequence and the highest possible affinity for their binding partners or targets, so that concentrations below 10 μM can be successfully
applied to cells without harm. Considering that cytotoxicity associated to Tat48–57- and Antp43–58 bound peptide conjugates was not restricted to a
particular type of cells, our data provide a general framework for the design of cell-penetrating peptides that may apply to broader uses of
intracellular peptide and drug delivery.
© 2007 Elsevier B.V. All rights reserved.Keywords: Cell-penetrating peptide; Tat; Intracellular delivery; Pancreatic beta-cell; HeLa cell1. Introduction
Cell-permeable peptides (CPP) have emerged as attractive
drug delivery tools. Transplantation of cells and tissues, and in
particular transplantation of pancreatic islets may greatly benefit
from the transducing properties of CPP as these may facilitate
the uptake of otherwise non-permeable cytoprotective mole-
cules such as peptides, proteins, or chemical compounds. CPP
may thus contribute to the overall improvement of donor cells
and tissues, both in yield and in quality.⁎ Corresponding author. Tel.: +41 21 314 33 90; fax: +41 21 314 33 85.
E-mail address: fabienne.maurer@chuv.ch (F. Maurer).
0005-2736/$ - see front matter © 2007 Elsevier B.V. All rights reserved.
doi:10.1016/j.bbamem.2007.06.003Pancreatic islet transplantation has shown promise to restore
glucose homeostasis in type 1 diabetic patients [1,2]. Yet, its
effective success is limited by the poor availability of donors
and by the significant loss of donor islets during the early steps
of purification and immediately following grafting. Typically,
up to 50% of the infused islet mass is destroyed by apoptosis
and non-immune inflammatory responses in the early days
post-transplantation. Because this process may ultimately lead
to early graft failure, it is one of the critical factors that
impinges on the success of islet transplantation. Furthermore,
the minimal number of functional islets required for a
successful graft, i.e. ca 30–50% of the mean islet content of
an intact pancreas, is difficult to retrieve from a single donor,
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successful grafting [1,3].
Because of its short length, its good efficacy at crossing cell
membranes of different cell types, its overall low toxicity [4],
and the fact that it does not leak out from cells once internalised
[5], Tat48–57 cell-permeable peptide has generated a lot of
attention for intracellular delivery of peptides, proteins, or
chemical compounds [6–10]. Several studies have further
shown that it could efficiently deliver peptides and proteins into
insulin-secreting cells without obvious changes in biological
function, either in culture, in isolated islets, or in a whole
pancreas [11–13]. Moreover, retro-inverso (D-) enantiomers of
Tat-conjugated peptides might provide molecules with longer-
lasting biological activities, presumably because of their better
resistance against proteases [11].
Tat48–57-bound anti-apoptotic peptides are of particular
interest for the field of pancreatic islet transplantation because
such inhibitors could be specifically delivered to donor islets
before grafting and retain their activity as long as they are not
degraded by proteolysis or inactivated by other processes. In
other words, they would help donor islets resist the first wave of
pro-apoptotic signals without affecting the recipient's tissues.
At least 5 cell-permeable proteins or peptides have shown
promising anti-apoptotic potential in insulin-secreting cells
[11,14–19]. Yet, it is remarkable that whereas it seems relatively
easy to block death of β-cell lines with inhibitors of either JNK,
NO or NF-κB, treatments with individual peptides are unable to
fully prevent human islet loss following islet isolation. The pro-
apoptotic pathways that need to be blocked during the course of
human islet preparation are complex [20–22], suggesting that it
might be necessary to treat islets before transplantation with a
cocktail of strong anti-apoptotic agents in order to succeed at
preventing early graft failure.
Here, we have selected several peptides for their ability at
blocking some of the main pro-apoptotic pathways induced by
islet isolation and purification and/or cytokines in pancreatic
β-cells, namely JNK, NF-κB, and STAT-1 [20,22,23]. We
have subsequently linked these sequences to the Tat48–57
transporter peptide, with the long-term aim of assessing their
ability at protecting stressed pancreatic islets from apoptosis.
Most of these conjugates triggered unexpected but significant
cytotoxicity when used at concentrations above 10 μM, both in
rat primary and INS-1E β-cells. In contrast, concentrations of up
to 100 μM Tat48–57 alone were essentially harmless. Interest-
ingly, the ubiquitous Antp43–59 CPP [24] exhibited intrinsic
cytotoxic properties in the same cells, and Antp-conjugates were
also more toxic than their Tat-bound counterparts. For all Tat-
and Antp-peptide conjugates, cytotoxicity occurred irrespective
of the sequence of the cargo. A similar trend was observed in
HeLa cells, but not in 208F rat fibroblasts. Yet, the absence of
cytotoxicity in the latter correlated with a reduced ability at
internalising CPP.
Although the mechanisms triggering cell death have not been
investigated in details, they seem to depend on the efficacy of
intracellular peptide uptake, as well as on the length of the
peptidic cargo. Furthermore, they may involve the activation of
intracellular stress signalling pathways. These responses areof particular concern for highly sensitive cells like pancreatic
β-cells.
Our results therefore indicate that in order to avoid un-
wanted and unspecific cytotoxicity, effector molecules bound to
Tat48–57 or Antp43–58 transporters should be designed with the
shortest possible sequence and the highest possible affinity for
their intracellular binding partners, substrates, or targets. These
data may provide a framework for the design of cell-penetrating
conjugates, not only in the field of pancreatic islet transplanta-
tion, but also in broader applications of intracellular peptide and
drug delivery.
2. Experimental procedures
2.1. Peptides
Peptides are listed in Table 1. Unless indicated otherwise, they were
synthesised manually on methoxybenzhydrylamine (MBHA) resin (Novabio-
chem, Merck) by Nα-butyloxy (Boc) solid phase peptide synthesis (SPPS) [25].
Couplings were monitored by the trinitrobenzenesulfonic acid (TNBSA) colour
test (Fluka). Peptides were subsequently cleaved and simultaneously depro-
tected from the resin by treatment with 90% hydrofluoridric acid (HF) and
appropriate scavengers for 1 h at 0 °C [25]. Crude peptides were taken up in a
20% aqueous acetic acid solution, diluted to 5% acetic acid with distilled water
and remaining scavengers were extracted by a diethylether wash. Peptides were
further lyophilised to remove acetic acid, purified by preparative reverse phase
HPLC on an Atlantis dC18 column (Waters) in 10–60% buffer B (0.1%
trifluoroacetic acid (TFA) in acetonitrile) over 45 min at 15 ml/min and further
characterised by ESI mass spectrometry (Thermo LTQ, Finnigan). Phosphory-
lated STAT1i peptide was synthesised manually on NovaSyn TGR resin
(Novabiochem, Merck) by standard Nα-fluorenylmethoxycarbonyl (Fmoc)
SPPS [26] and using preformed protected phospho-tyrosine [27]. Coupling
reactions were monitored by the ninhydrin colour test (Kaiser test kit, Fluka)
using a 10-fold excess of Fmoc-amino acid activated with a mixture of uronium-
based hydroxybenzotriazol coupling reagents in the presence of diisopropy-
lethylamine (DIPEA). STAT1i was cleaved and simultaneously deprotected
from the resin by treatment with TFA/triisopropylsilane/water (95:2.5:2.5). The
crude peptide was further extracted with diethylether after concentration of the
cleavage mixture, lyophilised, purified by preparative reverse phase HPLC as
above in 5–50% buffer B over 45 min at 15 ml/min, and characterised by ESI
mass spectrometry. Antp, dJBD19, dJBD19-mut, JBD19, NBD, NBDscr,
NBDscr-Tat, and dJNKi were custom-synthesised by Fmoc-SPPS followed by
TFA→acetate salt exchange after reverse phase HPLC purification (NeoMPS,
France). FITC-labelled dJNKi was custom prepared by Auspep, Australia. Tat-
BH4-Bcl-XL was purchased from Calbiochem. All stock solutions of peptides
were prepared in water except NBD, NBDscr, Antp, and Antp-conjugates that
were resuspended in the presence of DMSO. The maximal concentration of
DMSO that was added to cells does not affect INS-1E, HeLa, or 208F cell
viability (data not shown and [28]).
2.2. Rat primary β-cells
Rat pancreatic islets were isolated from adult Wistar rats by collagenase
digestion and primary β-cells were purified by auto-fluorescence-activated cell
sorting (FACS, FACStar, Becton-Dickinson and Co., Sunnyvale, CA, USA)
[29,30]. FACS-purified β-cell preparations, ca 90% pure [30,31] or whole rat
islets, were cultured in HAM's F-10 and RPMI-1640 mediums, respectively
[31,32].
2.3. Cell culture
Rat insulin-secreting INS-1E cells [33], kindly provided by Prof. C.
Wollheim (University Medical Centre, Geneva, Switzerland), were cultured in
RPMI-1640 medium with Glutamax I (Gibco) supplemented with 5% foetal
bovine serum, 10 mM HEPES, 1 mM sodium pyruvate, and 50 μM 2-
Table 1
Peptides
Name Amino-acid sequence Length (aa) Net charge References
dTat dRdRdRdQdRdRdKdKdRG 10 +8 [11]
L-Tat GRKKRRQRRR 10 +8 [6]
Antp RQIKIWFQNRRMKWKK 16 +7
dJBD19 dDdQdSdRdPdVdQdPdFdLdNdLdTdTdPdRdKdPdR 19 +3 [11]
dJBD19-mut dDdQdSdRdPdVdQdPdFdAdNdAdAdAdAdAdKdPdR 19 +3 [38]
JBD19 RPKRPTTLNLFPQVPRSQD 19 +3 [11]
NBD TALDWSWLQTE 11 −2 [34]
NBDscr WELDTSTQLWA 11 −2 this work
β-arrestin 2 HFLMSDRRSLHLEASLDKEL 20 −1 [44]
dJNKi dDdQdSdRdPdVdQdPdFdLdNdLdTdTdPdRdKdPdR ·dPdP ·dR
dRdRdQdRdRdKdKdRG
31 +11 [11,38]
dJNKi-mut dDdQdSdRdPdVdQdPdFdAdNdAdAdAdAdAdKdPdR ·dPdP ·dR
dRdRdQdRdRdKdKdRG
31 +10 [38]
dTat-βarr2 dRdRdRdQdRdRdKdKdR·GG ·HFLMSDRRSLHLEASLDKEL 31 +7 [44]
L-JNKi GRKKRRQRRR ·PP ·RPKRPTTLNLFPQVPRSQD 31 +11 [11,38]
Tat-BH4-Bcl-XL GRKKRRQRRR-βA-SNRELVVDFLSYKLSQKGYS 31 +9 [41–43]
STAT1i KGTG[Y⁎]IKTELGGRKKRRQRRR 21 +9 [35]
STAT1 control KGTGYIKTELGGRKKRRQRRR 21 +9 [35]
NBD-Tat TALDWSWLQTE ·G ·GRKKRRQRRR 22 +6 [34]
NBDscr-Tat WELDTSTQLWA G ·GRKKRRQRRR 22 +6 this work
Tat-NBDscr GRKKRRQRRR ·G ·WELDTSTQLWA 23 +6 this work
Tat-RDM GRKKRRQRRR ·GG ·AVFRFIPRHPDELELDVDD 31 +4 this work
Antp-JNKi DRQIKIWFQNRRMKWKK ·PP ·RPKRPTTLNLFPQVPRSQD 38 +9 this work and [11]
Antp-NBD DRQIKIWFQNRRMKWKKTALDWSWLQTE 28 +4 [34,39,40]
dTat, L-Tat, andAntp are peptide carriers; dJBD19, dJBD19-mut, JBD19, NBD, NBDscr, andβ-arrestin 2 are non permeable cargos corresponding to, respectively, (i) dJNKi,
(ii) dJNKi-mut, (iii) L-JNKi and Antp-JNKi, (iv) NBD-Tat and Antp-NBD, (v) NBDscr-Tat and Tat-NBDscr, and (vi) dTat-βarr2 conjugated peptides. Tat-BH4-Bcl-XL,
STAT1i, STAT1 control, and Tat-RDM have been used in Tat-conjugated forms only. For CPP-conjugates, the transport sequence is underlined. dX residues indicate retro-
inverso (D-) amino acids; [Y*] stands for phosphorylated tyrosine; 1- or 2 aa-long linkers between peptide carrier and cargo are shown in bold and italic letters.
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Glutamax I medium supplemented with 10% foetal bovine serum and 1 mM
sodium pyruvate. 208F rat fibroblasts (ECACC, Salisbury, UK) were cultured in
DMEMmedium with Glutamax I and 4.5 g/l glucose (Gibco) and supplemented
with 10% foetal bovine serum.
2.4. Cytotoxicity
Adherent FACS-purified rat β-cells (10,000 cells/condition) and rat
fibroblasts (6000 cells/condition) were cultured in 96-well dishes. Rat islets
(10 islets/condition) were cultured free-floating in 96-well dishes. Adherent
INS-1E (30–40,000 cells/condition) and HeLa (20–30,000 cells/condition) cells
were cultured in 3 cm tissue culture plates. Primary β-cells and rat islets were
exposed to cell-permeable peptides (see Table 1) for 24 h. INS-1E cells, HeLa
cells, and rat fibroblasts were exposed to the peptides for 48 h. The percentage of
dead cells was determined by inverted fluorescence microscopy using the DNA
dyes Hoechst 342 (20 μg/ml) and propidium iodide (PI; 10 μg/ml) [11]. A
minimum of 500 cells was counted in duplicate for each experiment.
2.5. Cell peptide uptake and confocal laser scanning microscopy
5 μM of FITC-labelled dJNKi peptide was added to the culture medium of
40–50%-confluent cells for 1 h at 37 °C. Cells were rinsed three times in PBS
and fed with fresh medium. Peptide internalisation was monitored by
fluorescence in live cells using a Leica SP5 AOBS confocal laser scanning
microscope equipped with 10 and 63× water submersible objectives. Excitation
was performed at 488 nm and emission was detected between 500 and 650 nm.
Free FITC was used as a control for background signals.
2.6. MAPK assays and immunoblotting
Cellular extracts were prepared by scraping control and CPP-treated cells in
lysis buffer containing 20 mM Tris-acetate, 0.27 M sucrose, 1% Triton X-100,
1 mM EGTA, 1 mM EDTA, 50 mM NaF, 10 mM β-glycerophosphate, 1 mMdithiothreitol, 10 mM p-nitrophenyl-phosphate, and 1× antiprotease mix (Roche).
Insoluble material was removed by a 5-min centrifugation at 14000 rpm and
protein contents were measured by the Bradford procedure (Bio-Rad).
For JNK and ERK solid phase activity tests, 10 μg of protein extracts were
incubated for 2 h at 4 °C in the presence of 1 μg of either glutathione S-
transferase (GST)-cJun1–79 or GST-Elk1 beads as respective JNK- and ERK-
specific substrates. Beads were subsequently washed 3 times in scraping buffer
containing 0.1% Triton X-100 and rinsed twice in a buffer containing 20 mM
HEPES pH 7.5, 20 mM β-glycerophosphate, 10 mM MgCl2, and 1 mM DTT.
Kinase reactions were initiated by the addition of 5 μCi 5′-[γ-33P]ATP
(3000 Ci/mmol, Amersham Biosciences) and incubated for 30 min at 30 °C.
Reaction products were resolved by 10–12% SDS-PAGE analysis, gels were
dried, and phosphorylation signals were analysed by autoradiography (Kodak)
and phosphorimaging using an Instant Imager system.
p38 MAPK phosphorylation levels were assessed by western blotting. 20 μg
of total proteins were separated by SDS-PAGE and electro-transferred onto
nitrocellulose membranes. Membranes were blocked for 1 h at room temperature
in 1× TBS (pH 7.6), 0.1% Tween 20, 5% non-fat dry milk, transferred into in
1× TBS, 0.1% Tween 20, 4% non-fat dry milk, and probed overnight at 4 °C with
1:2000 or 1:1000 respective dilutions of anti-phospho-p38 MAPK or anti-p38
MAPK antibodies (Cell Signaling). After 4 to 5 washes in 1× TBS, 0.1% Tween
20, membranes were further exposed for 1 h at room temperature to a 1:3500
dilution of horseradish peroxidase-linked secondary anti-rabbit antibody (Cell
Signaling), and washed again in TBS-Tween buffer. Peroxidase activity was
detected by enhanced chemiluminescence (Amersham Biosciences).
3. Results
3.1. Tat48–57-bound cell-permeable peptides induce cytotoxicity
in primary pancreatic β-cells
We have selected peptides to block three of the main pro-
apoptotic pathways induced by islet isolation and purification
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(L- and dJNKi peptides [11]), NF-κB (NEMO-binding domain
(NBD) peptide [34]) and STAT-1 (STAT1i [35]). These peptides
were linked to the Tat48–57 transporter sequence of HIV-1 virus
[36]. As controls, we prepared L- and D (retro-inverso)-forms of
the Tat48–57 sequence alone, a scrambled NBD sequence bound to
Tat48–57 in two orientations, as well as non-permeable NBD and
NBDscr cargos (Table 1). As pancreaticβ-cells are known for their
marked sensitivity to a variety of compounds such as transfecting
agents (data not shown), we first determined the threshold of
cytotoxicity induced by these peptides in primary β-cells (Fig. 1).
Briefly, FACS-purified primary rat β-cells were exposed to
increasing doses of peptides for 24 h and cytotoxicity was
measured by counting the percentage of Hoechst/PI-positive cells
under a fluorescence microscope. As observed in Fig. 1, the basal
level of primary β-cell death was ca. 11%. Exposure to up to
50 μM of either the carriers alone (i.e. L- or dTat) or the non
permeable cargos (i.e. NBD and NBDscr) did not induce any
cytotoxicity. In contrast, L-JNKi, NBD-Tat, and NBDscr-Tat
induced significant cytotoxicity at concentrations starting from
10 μM and all Tat-conjugates were toxic at 50 μM. At least for
NBD-Tat, cytotoxicity does not seem to be related to its inhibitory
function since NBDscr-Tat and Tat-NBDscr control peptides were
both toxic. In these peptides, the position of the carrier does not
seem to affect peptide toxicity in a significant fashion.
Similarly to what was observed in primary β-cells, exposure
of rat islets to 50 μM of either NBD-Tat or NBDscr-Tat induced
significant cytotoxicity (control 17±5, NBD-Tat 29±10, Tat-
NBDscr 61±4% of dead cells; data are means±SEM, n=2–5),
whereas Tat transporters alone were harmless (data not shown).
Clear signs of cytotoxicity were also seen in human islets
exposed to 30 and 100 μM dJNKi for 24 h, but in this case, dTat
induced some cytotoxicity at 50 μM (data not shown and [37]).
Taken together, these results show that pancreatic islets and
β-cells are highly sensitive to cell-permeable peptide conjugates
at concentrations above 10 μM.Fig. 1. CPP-induced cell death in primary pancreatic β-cells. FACS-purified rat β-cel
concentrations in the culture medium. Cells were kept in culture for another 24 h and
under a fluorescence microscope. Data are shown as means±SD (n=2 to 18). Non-
t-test; ns: non-significant.3.2. Tat48–57- and Antp43–58-bound cell-permeable peptides
induce cytotoxicity in INS-1E and HeLa cells
Due to the difficulties in obtaining primary β-cells, we
further investigated CPP-induced cytotoxicity in the well
differentiated INS-1E pancreatic cell line [33]. Several peptides
were used for these experiments (Table 1): L- and dTat48–57
carriers as above, non-permeable JBD19, dJBD19, dJBD19-mut,
NBD, NBDscr, and β-arrestin-2 (βarr2) peptides as controls,
and a series of Tat48–57-bound peptide conjugates. The latter
include IB1/JIP-1-based inhibitors of the JNK pathway (i.e. L-
and dJNKi [11]), a non-inhibitory dJNKi-mut peptide [38],
inhibitors of the NF-κB (i.e. NBD-Tat and NBDscr-Tat as a non-
functional control [34,39,40]) and STAT-1 pathways (i.e.
phosphorylated STAT1i and non-phosphorylated STAT1 con-
trol [35]), a Bcl-XL blocker (i.e. Tat-BH4-Bcl-XL [41–43]), a
putative inhibitor of JNK3 (i.e. dTat-βarr2 [44]) and an
unrelated Tat-RDM control peptide. To assess whether
cytotoxicity was specific of the Tat system, we also tested
Antp43–58 peptide carrier [24] and two conjugates, Antp-JNKi
and Antp-NBD [34,39,40]. Both JNKi and Bcl-XL inhibitors
have been shown previously to promote cytoprotection against
IL-1β-induced apoptosis in pancreatic β-cells at concentrations
ranging between 0.3 and 1 μM [11,18].
Cytotoxicity was measured 48 h after peptide addition, as
described for primary cells. Cell death reached 2.3% on
average in untreated INS-1E cells (Fig. 2A). This percentage
was not significantly increased in the presence of up to
100 μM of either L- or dTat, which is in agreement with
previous observations of poor Tat-associated cellular toxicity
[4]. Concentrations of 100 μM of non-permeable peptides
were also harmless. In contrast, exposure to Tat-conjugates
led to severe cytotoxic effects at concentrations above 10 to
30 μM for all peptides tested except for dJNKi-mut, that only
triggered mild toxicity (i.e. 7–8% cell death at 10 and
30 μM). Cytotoxicity is unlikely to be due to the inhibition ofls were isolated and pre-cultured for 48 h prior to adding peptides at the indicated
cell death was measured by counting the percentage of Hoechst-PI-positive cells
perm: non-permeable peptides. ⁎ and ⁎⁎: p≤0.05 and p≤0.01 versus control,
Fig. 2. CPP-induced cytotoxicity in (A) rat pancreatic INS-1E cells, (B) human HeLa cells, and (C) rat 208F fibroblasts. Peptides were added to the culture medium at
the indicated concentrations and cells were cultured for 48 h at 37 °C. Cell death was measured by counting the percentage of Hoechst-PI-positive cells under a
fluorescence microscope. Data are shown as means±SD (n=1 to 59). ⁎ and ⁎⁎: p≤0.05 and p≤0.01 versus control, t-test; ns: non-significant; nd: not done.
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Tat-RDM and STAT1 control peptides all caused cellular
damage.
Antp carrier alone was significantly more toxic that Tat,
triggering cell death above 10 to 30 μM, whereas Antp-NBD
and Antp-JNKi conjugates induced comparable effects above 3
to 10 μM. Thus the toxic response elicited by cell-permeablepeptides in these cells is not restricted to the Tat transporter
system.
Typically, toxic peptides induced the formation of intracel-
lular vesicles in INS-1E cells, ultimately leading to cell
detachment and death (Fig. 3). In cases of strong cytotoxicity
(i.e. above 30 to 40%), these signs became visible as early as 2
to 6 h following peptide addition (data not shown).
Fig. 3. CPP-induced cytotoxicity in rat pancreatic INS-1E cells. Cells were
treated as in Fig. 2 and pictures were taken 48 h after incubation with the
indicated peptides. Major signs of cytotoxicity can be observed in the presence
of 30 μM dJNKi, 30 μM Antp-JNKi, or 100 μM NBD-Tat (boxed pictures),
whereas there is limited toxic effect in the presence of 200 μM of Tat
transporters alone. Pictures are representative of 4 independent experiments.
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β-cells, we ran similar experiments in non pancreatic human
HeLa cells and rat 208F fibroblasts (Fig. 2B and C).
Cytotoxicity was generally slightly reduced in HeLa compared
to INS-1E cells, but followed a similar trend otherwise. L- and
dTat transporters alone triggered some toxicity above 100 μM in
this cell line, whereas the effects of Antp and Antp-conjugates
were similar to those seen in pancreatic cells. In contrast, no
cytotoxicity was observed in 208F fibroblasts, even in the
presence of up to 100 μM of CPP-conjugates (Fig. 2C).
3.3. Absence of cytotoxicity correlates with poor
cell-permeable peptide uptake in 208F rat fibroblasts
We further investigated whether there was a correlation
between the extent of cytotoxicity and the efficacy of CPPtransduction by comparing the uptake of FITC-labelled dJNKi
in the 3 abovementioned cell lines. Briefly, cells were
exposed to 5 μM of FITC-labelled dJNKi for 1 h at 37 °C.
They were then thoroughly rinsed with PBS, fed with fresh
medium and analysed by confocal laser scanning fluorescence
microscopy. As shown in Fig. 4, the uptake of FITC-dJNKi
was evident in both INS-1E and HeLa cells, with a
percentage of fluorescent cells close to 100%. Internalised
peptide was detected both in the cytoplasm and in the nucleus
where it tended to accumulate into relatively large granules.
Punctuate fluorescent patterns in the perinuclear space of
HeLa cells (Fig. 4B) are suggestive of an accumulation within
endosomal vesicles, as reported in the literature [10,45]. It is
more difficult to draw conclusions for INS-1E cells as these
are small, tend to grow in aggregates and exhibit limited
cytoplasmic spreading. It seems nonetheless that the fluores-
cence of internalised dJNKi is evenly distributed throughout
the cytoplasm in these cells. In contrast, we could not detect
any dJNKi uptake in 208F cells. In other words, the better
tolerance of 208F fibroblasts towards CPP-conjugates corre-
lates with their higher resistance to peptide entry. Along these
lines, we also noted that these fibroblasts were considerably
more resistant to detergent-free proteinase K treatment than
INS-1E and HeLa cells, suggesting that membrane composi-
tions might significantly differ between these cell lines (data
not shown).
3.4. Effect of cell-permeable peptides on MAPK activity
The mechanisms by which CPP-bound peptides induce cell
death have not been investigated in details. Yet, most of the
Hoechst/PI-positive cells exposed to peptidic conjugates
displayed clear signs of apoptosis such as nuclear condensation
and late fragmentation. Therefore, we sought to determine
whether cytotoxicity correlated with the activation of two well-
known pro-apoptotic stress signalling pathways in β-cells,
namely JNK and p38 MAPK. In parallel, we also assessed ERK
activity.
In pilot time-course assays performed in INS-1E and HeLa
cells exposed to 30 μM of Tat-conjugates, we detected a peak of
JNK activation within 2 to 6 h post peptide addition (data not
shown). In subsequent experiments, we measured JNK
activities in total protein extracts prepared from cells treated
for 3 h with several of the peptides described above (Fig. 5). A
series of observations can be drawn from these results. First,
neither treatment with 200 μM of L- or dTat alone resulted in a
marked activation of JNK in INS-1E cells. In contrast, all
treatments with cytotoxic conjugates correlated with a clear
activation of JNK in these cells (Fig. 5A and B). The fold-
increase of JNK activity was the highest in the presence of
NBD-Tat (25-fold at 100 μM), Tat-BH4-BclXL (22 fold at
10 μM), Antp-JNKi (13 fold at 10 μM), and STAT-1i (5 fold at
30 μM) and a more moderate increase of JNK activity was
detected in the presence of L- and dJNKi (2.5 and 4 fold at
30 μM, respectively). The reduced activation of JNK in the
presence of JNKi can be explained by the known inhibitory
effect that these peptides exert on JNK activation when used
Fig. 4. Efficacy of peptide transduction into INS-1E, HeLa, or 208F cells. Cells were incubated for 1 h in the presence of 5 μM FITC-labelled dJNKi or FITC alone.
Peptide internalisation was visualised in live cells by confocal scanning microscopy. Results of fluorescence microscopy are presented alone or in superposition with
bright field images at 100-fold (A) and 630-fold (B) magnifications. Peptide uptake is significantly stronger in INS-1E and HeLa cells than in fibroblasts. Pictures are
representative of 3 independent experiments.
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L- and dJNKi both promoted significant cell death above
10 μM, suggesting that other and/or additional death pathways
were involved. High levels of JNK activity observed in thepresence of 10 and 30 μMAntp-JNKi may relate to the intrinsic
toxicity of the Antp carrier.
JNK activity was also measured in proteins extracted from
HeLa and 208F cells exposed to CPP and CPP-conjugates. In
Fig. 5. JNK, ERK, and p38 MAPK activities in INS-1E and HeLa cells incubated in the presence of Tat-conjugates. (A and C) Typical results of JNK and ERK kinase
activity tests (KA) and anti-phospho-p38 MAPK western blots in total protein extracts of (A) INS-1E and (C) HeLa cells treated for 3 h with the indicated peptides.
Bands of interest are indicated by asterisks. (B and D) Intensities of c-Jun and Elk-1 substrate phosphorylation were quantified by phosphor-imaging and normalised to
those measured in (B) non-treated INS-1E and (D) HeLa cells. Data are shown as means±SEM (n=2 to 4). ⁎ and ⁎⁎: p≤0.05 and p≤0.01 versus control, t-test.
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lower than in INS-1E cells, which is in agreement with previous
reports about elevated basal levels of JNK activity in pancreaticβ-cells [46]. In HeLa cells, the patterns of peptide-induced JNK
activation correlated well with those of cytotoxicity, although
the fold-increase in activity was generally more moderate than
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effects were detected in fibroblasts (data not shown), which was
consistent with their reduced ability at internalising Tat
peptides.
Extracts used to probe JNK activity were tested in parallel for
the levels of p38 MAPK phosphorylation by western blotting,
and for those of ERK activity by kinase activity assays using
GST-Elk-1 as a substrate. As shown in Fig. 5A and C, the most
potent peptides, including 30 μM of L- or dJNKi, induced a
slight increase in p38 MAPK phosphorylation in INS-1E and
HeLa cells. Yet, the overall fold-augmentation of p38 phos-
phorylation was lower than that of JNK activation, at least in
INS-1E cells. Similarly to the effect on JNK activity, exposure
to Tat transporters alone produced no effect on p38 phosphor-
ylation in INS-1E cells and induced a moderate increase in
phosphorylation in HeLa cells. In contrast, ERK activities were
not significantly changed by any treatment in all 3 cell lines
(Fig. 5 for INS-1E and HeLa cells, data not shown for 208F
fibroblasts).
Taken together, these results indicate that cell-permeable
peptides may induce cytotoxicity when used at concentrations
above 3 to 10 μM. Remarkably, cytotoxicity is not restricted to
β cells but is likely to affect broader types of cells, depending on
their ability at internalising CPP. Moreover, the cytotoxic
response is not restricted to one type of transporters, as both Tat-
and Antp-conjugates lead to major deleterious effects in INS-1E
and HeLa cells. CPP-induced cytotoxicity in INS-1E cells
correlated with a significant activation of JNK and a moderate
phosphorylation of p38 MAPK, two of the best known pro-
apoptotic pathways in pancreatic β-cells. Unexpectedly, high
doses of JNK peptide inhibitors also lead to β-cell death,
suggesting that JNK-independent death pathways are recruited
by these peptides. Slightly reduced levels of peptide-induced
cytotoxicity correlated with a more moderate activation of JNK
and p38 MAPK pathways in HeLa cells, and minor JNK
activation was paralleled by negligible cytotoxicity and poor
CPP uptake in 208F fibroblasts.
4. Discussion
To date, many investigations about the biology of cell-
permeable peptide transporters have focused at elucidating their
respective mechanism of membrane translocation [47]. Yet,
only a few reports addressing possible CPP toxicity have been
published. Most of them, by studying transducing peptide
sequences in various cell types, have basically found limited if
no toxicity associated to concentrations of up to 10 to 100 μM
Tat48–57 and Antp43–58 transporters and for exposure of up to
24 h [4,36,48]. Trehin et al only noted significant cytotoxicity
for both CPP when applied at 1 mM on canine kidney MDCK
cells [48], but the ability of Tat peptides to transduce this cell
line is debatable [49]. Recently, Saar et al. have reported very
little if no cytotoxicity associated to the uptake of 10 μM of
Tat48–60 or Antp43–58 in 3 human cell lines [4]. They also
inferred very little cytotoxicity on erythrocytes as 50 μM of
Tat48–60 did not induce hemolysis and Antp43–58 produced only
a marginal detrimental activity. The low intrinsic toxicity ofTat48–57 in INS-1E and HeLa cells is consistent with these
previous reports. In contrast, we detected clear cytotoxicity in
the presence of 30 μM Antp43–58 alone in these cells. Drin et al
similarly reported notable cell lysis in K562 cells exposed to
increasing concentrations of Antp43–58 (typically 5 μM and
above), whereas Tat produced no such effect [50]. These
differences were attributed to the elevated lipid-binding affinity
of Antp (related to its hydrophobicity and amphipathicity), that
could account for plasma membrane destabilisation and
permeabilisation. Such a process might also explain the intrinsic
cytotoxicity of Antp in INS-1E and HeLa cells.
At least 5 cell-permeable proteins or peptides had shown
promising anti-apoptotic potential in insulin-secreting cells
[11,14–19]. Yet, we have provided evidence here that when
effector sequences, including anti-apoptotic peptides, are linked
to Tat48–57- or Antp43–58, the resulting conjugates induce
cytotoxic responses in pancreatic β-cells, irrespective of the
sequence of the cargo. Although unexpected, these results do not
contradict the reports mentioned above, but rather point at the
importance of the dose of peptide delivered. Specifically, most of
the initial experiments were performed in the presence of
relatively low concentrations of CPP-conjugates. The cytopro-
tective effects of heme-oxygenase-1 and neuroglobin Tat-fusion
proteins against oxidative stress were obtained in the nM range
[16,17]. Also, 1 μMof Tat-bound JNKi peptides conferred good
protection against IL-1β-induced apoptosis in β-TC3, RIN-
5AH-T2B, and INS-1 cells [11,46,51]. Cytoprotection was
further accompanied by JNK inhibition, as illustrated by the
significant reduction of both c-Jun phosphorylation and c-fos
mRNA expression. In addition, pre-treating rat pancreatic
explants with 1 μM dJNKi markedly inhibited JNK activity
(ca 60%) and c-fos mRNA expression (ca 70%) upon islets
isolation, thereby conferring enhanced viability to purified islets
[37]. The same treatment also conveyed mild protection against
IL-1β-induced apoptosis. In contrast, exposure to 5 μM of
dJNKi induced marked apoptosis in rat islets [37], whereas
10 μMof L- and dJNKi produced serious damage in primary and
INS-1E pancreatic cells (Figs. 1 and 2). In other words, 5 μM
stands around the limit of toxicity for Tat48–57-JNKi peptides in
rat islets and β-cells, but partial cytoprotection can be attained
below this concentration. This threshold of toxicity appears to
vary between species. We have indeed recently shown that
concentrations of up to 30 μM of dJNKi produced limited
cytotoxicity in human islets [37], whereas others reported that
10 μM of 11-Arg-bound JNKi significantly improved pig and
mouse islets recovery and function for transplantation [14,52].
These discrepancies may reflect species-associated differences
in the efficiency of peptide uptake or in the sensitivity to
intracellular death signals triggered by these peptides. In the
latter case, they might also result from distinct intrinsic
properties of Tat48–57 and 11-Arg carriers, although data
comparing both carriers in the same experimental model are
currently lacking. Along these lines, it has also been documented
that rat islets were usually significantly more sensitive to toxic
stimuli than mouse or human islets [53].
A concentration of 200 nM Tat-BH4-Bcl-XL was sufficient
to decrease caspase 6 activation by approximately 50% in non-
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was used to obtain partial protection from IL-1β-induced
apoptosis in human islets, although not clearly specified in the
original report [18]. In our hands however, the same dose did
not seem to promote INS-1E cell survival against IL-1β-
induced apoptosis (% apoptosis at 48 h: control 1.4±0.2, 2 ng/
ml IL-1β 7.6±1.1, 200 nM Tat-BH4-Bcl-XL 8.4±1.4; data are
means±SD, n=3–4). At this stage, it is not clear whether these
results denote the need for a higher dose of peptide to reach
protection, or whether pathways blocked by Tat-BH4-BclXL are
not sufficient to block IL-1β-induced apoptosis in this cell line.
The comparison between our results and data published
previously for NBD peptides is less trivial. Rehman et al.
showed that in vitro transduction of isolated mouse islets with
200 μM of a PTD5-NBD peptide for 2 h prevented NF-κB
activation by IL-1β [19]. In addition, injection of 200 nmol
PTD5-NBD into the common bile duct prior to pancreatic islet
isolation, followed by 12 to 18 h of culture in the presence of
200 μM peptide improved islets viability by 10 to 15% and
glucose-stimulated insulin release by 10 to 30% [19]. As the
efficiency of peptide uptake mediated by PTD5 versus Tat and
Antp carriers has not been compared in pancreatic β-cells and
islets, it is difficult to extrapolate whether the apparent conflict
between these data and ours are the consequence of differences
in peptide entry or carrier-dependent levels of toxicity.
Interestingly, Tat appears ca 3-fold more efficient than PTD5
to transduce small cargo sizes (60 kDa) in HeLa cells whereas
both carriers seem equally effective at internalising large
proteins (500 kDa) [54]. Similarly to the data obtained with
dJNKi, it is also conceivable that the threshold of NBD-induced
cytotoxicity is lower in rat than in mouse β-cells and islets. Of
note, cytotoxicity of Tat-bound NBD peptides does not appear
to be related to the long-term inhibition of NF-κB activity since
NBDscr-Tat and Tat-NBDscr control peptides were equally toxic
(Figs. 1 and 2). This is in agreement with independent data
showing that long-term specific inhibition of NF-κB activity in
adult mouse β-cells does not affect insulin release or glucose
tolerance in vivo [55].
We have presently shown that the INS-1E cytotoxic response
correlated with a significant activation of JNK-, and to a lesser
extent p38 MAPK. These stress signalling pathways are well
known for their potent pro-apoptotic function in pancreatic
β-cells and are likely to contribute to INS-1E cell death
[11,20–22,46]. A less pronounced JNK and p38 MAPK acti-
vation was detected in HeLa cells. At this stage, we do not
have indications about the internalisation process of Tat- or
Antp-conjugates in INS-1E or HeLa cells. It is therefore
difficult to speculate as to how these cells sense exposure to
CPP conjugates as toxic and how this relates to the activation of
downstream stress signalling pathways. Yet, cell entry appears
mandatory for the onset of toxicity as high concentrations of
non permeable peptides were harmless and cells resistant to
dTat-mediated peptide internalisation were also resistant to
cytotoxicity. In other words, cytotoxicity is determined by the
intracellular concentrations of CPP-conjugates.
The poor capability of 208F fibroblasts at internalising
FITC-labelled dJNKi is intriguing. As reported in other ex-perimental models, Tat48–57 peptide internalisation appears to
be modulated by specific plasma membrane contents and
organisation. In particular, differences in cell surface heparan
sulfate proteoglycans [10,56,57] and cholesterol contents [58]
have been shown to affect Tat-mediated peptide uptake. We
have not compared the levels of cell surface heparan sulfate or
cholesterol in 208F versus INS-1E and HeLa cells, but we
suspect that differences in cell surface composition (i.e. types
and contents of proteoglycans, glycoproteins, or phospholipids)
are likely to account for the differences in CPP uptake, stress
pathways activation and onset of toxicity.
Addressing or comparing the mechanisms of Tat48–57- and
Antp43–58-mediated internalisation was beyond the scope of the
present work. Yet, it is interesting to note that FITC-labelled
dJNKi was detected both in the cytoplasm and in the nucleus of
INS-1E and HeLa cells, and that it tended to accumulate into
relatively large nuclear granules in both cell lines. Similar
nuclear accumulation of CPP has been described in several
other experimental models [45,50,59]. In addition, punctuate
fluorescent patterns in the perinuclear space of HeLa cells (Fig.
4B) might be suggestive of an accumulation within endosomal
vesicles, as reported in the literature for Tat and Antp
[10,45,50,59]. Conversely, the resistance of 208F fibroblasts
to Antp treatment may suggest that 208F are also poorly
efficient at internalising Antp. In the literature, data on Tat and
Antp internalisation processes are somehow conflicting, and
several, partially overlapping mechanisms have been proposed
[10]. It is conceivable that a process common and necessary to
the entry of both types CPP is missing or altered in these cells.
Recently, Ziegler et al have reported that short exposure
(b4 min) of NIH-3T3 fibroblasts to 50 and 500 μM Tat47–57
peptide was accompanied by a rapid, transient, and dose-
dependent decrease in the rate of extracellular acidification [60].
The authors further suggested that these pH modifications might
result from a direct effect of the CPP on intracellular activities
such as glycolysis, proton pumps performance, or endosomal
proton flux. We have not presently investigated local pH
changes upon peptide addition, but we have observed that
several of the peptides leading to β-cell toxicity also caused
severe inhibition of glucose oxidation in whole rat islets (data
not shown). Thus, cytotoxicity correlates with both the
activation of stress pathways and the impairment of essential
cellular functions.
A major outcome of this study is that Tat-conjugates are
significantly more toxic than Tat transporters alone. As shown
in Fig. 6, increased cytotoxicity correlates with longer peptides,
at least in INS-1E cells. Specifically, 31 aa Tat-conjugates,
namely L- and dJNKi, Tat-BH4-Bcl-XL and Tat-RDM were all
toxic at 10 μM, 21–22 aa STAT-1i and NBD-Tat became toxic
at 30 to 100 μM, and 10 aa Tat transporters were harmless up to
100 μM. A possible link between CPP toxicity and peptide
length had already been suggested by others who showed that
stretches of ca 75 arginine residues induced cytotoxicity at
concentrations ranging from 0.8 to 50 μM in Jurkat T-cells,
whereas tracts of 7 to 30 arginines were essentially harmless
[61]. In these experiments, it was however not possible to
discriminate whether cytotoxicity related to the length or to the
Fig. 6. Cytotoxicity increases with peptide length and concentration in INS-1E
cells. The percentage of cytotoxicity induced by cell-permeable peptides and
conjugates in INS-1E cells is presented relative to their length in amino acids
(aa). Data are shown as means±SD for (A) Tat-, and (B) Antp peptides and
conjugates. r: coefficient of correlation, Pearson.
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contrast, our results suggest that the potency of CPP depends on
their size rather than on their charge, as we were not able to
detect any correlation between the levels of cytotoxicity and the
net charge of the peptides (Fig. 1 and Table 1).
Data obtained recently in mouse myoblasts have suggested
that the mechanisms of cellular uptake of Tat-conjugates might
also depend on the size of the cargo. In particular, whereas Tat
fusion proteins were mostly internalised in cytoplasmic
vesicles, peptides less than 50 aa long seemed to rapidly enter
cells in a manner that was dependent on the membrane potential
[45]. Evidence obtained in neuronal PC12 cells had also
suggested that the Tat peptide might induce temporary cell
membrane perturbations by causing transient phosphatidyl-
serine redistribution, in a process described as “membrane-flip”
[62]. This flip together with Tat-transduction could be blocked
by pre-treating PC12 cells with an excess of poly-lysine [62].
Although we did not have data indicative of distinct modes of
entry for the peptides tested here, we reasoned that if membrane
reorganisation occurred in INS-1E (or HeLa) cells, it would
presumably be accompanied by a (transient) dose- and cell type-
dependent shift in membrane potential that, at its extreme, might
lead to irreversible cellular damage. To investigate thispossibility, we treated INS-1E cells for 30 to 60 min with
concentrations of L-JNKi ranging from 1 to 30 μM (i.e. from
non toxic to toxic doses) and monitored the kinetics of
membrane potential modifications by patch-clamp analysis
(data not shown). As these assays failed to show any significant
difference between untreated and treated cells, we concluded
that perturbations of membrane potential were unlikely to con-
tribute to CPP-dependent cytotoxicity. In this context, one may
add that the possibility of a direct penetration mechanism across
the lipid bilayer has been recently debated, several experimental
data arguing against such a possibility [57,58,63].
In summary, we have shown that Tat48–57-bound CPP
produced significant dose- and size-dependent cytotoxicity in
insulin-secreting cells and in HeLa cells. Cytotoxicity also
occurred when replacing Tat48–57 by Antp43–58. The mechan-
isms that trigger cell death seem to depend on the efficacy of
peptide entry and correlate with the length of the peptidic
cargo. Furthermore, they may involve the activation of
intracellular JNK, and to a lesser extent p38, stress signalling
pathways, two of the major pro-apoptotic cascades in pancreatic
β-cells. Taken together, these results indicate that in order to
avoid unwanted and unspecific cytotoxicity, effector molecules
bound to Tat48–57 or Antp43–58 should be designed with the
shortest possible sequence and the highest possible affinity for
their binding partners or targets, so that concentrations below
10 μMmay be successfully applied to cells. These data provide a
framework for the design of effective cell-penetrating peptides
not only for the field of pancreatic islet studies, but also for
broader applications of intracellular drug delivery.
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